Intraoperative Application of Cold Atmospheric Plasma to Prevent Postoperative Wound Complications in the Inguinal Region of High-risk Patients With Peripheral Arterial Occlusive Disease

NCT07571408 · tracked via the Priya Life Science Germany tracker

Sponsor

Ursula Werra

Phase

Not applicable

Started

2026-11-01

Last updated

2026-05-06

Condition(s) studied

Peripheral Occlusive DiseaseWound HealingWound Healing ComplicationCold Atmospheric PlasmaPrevention

Investigational drug(s) / intervention(s)

Cold atmospheric plasmaSham device

Cold atmospheric plasma: Single intraoperative treatment of the wound edges and the subcutaneous tissue adjacent to the wound edges with cold atmospheric plasma after subcutaneous closure and prior to skin closure

Sham device: Single intraoperative treatment of the wound edges and the subcutaneous tissue adjacent to the wound edges with sham device after subcutaneous closure and prior to skin closure

Study summary

The goal of this clinical trial is to learn if postoperative wound complications in the inguinal region of high-risk patients with peripheral arterial occlusive disease can be prevented by the intraoperative application of cold atmospheric plasma.

The main questions it aims to answer are:

Does the intraoperative application of cold atmospheric plasma reduce the need for surgical revision of inguinal wounds due to wound healing complications within 3 months postoperatively? Does the intraoperative application of cold atmospheric plasma reduce wound healing complications not requiring revision within 3 months postoperatively?

Researchers will compare the application of cold atmospheric plasma to a placebo (a deactivated look-alike device).

Participants will:

Undergo surgical treatment with femoral artery access due to their peripheral arterial occlusive disease, in accordance with the respective vascular surgery department standard of care.

Receive a single application of cold atmospheric plasma or, respectively, placebo in the area of their inguinal access wound during surgery (after subcutaneous closure and prior to skin closure).

Be regularly assessed for wound healing during the first postoperative 14 days as part of routine clinical care and undergo a final evaluation at 3 months. They will also be surveyed regarding their quality of life.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Age \> 18 years * Written informed consent * Surgical treatment of peripheral arterial occlusive disease (PAOD) with femoral (inguinal) access * High-risk patient for wound healing complications: WHD (wound healing disorder) score ≥ 4 points: Diabetes mellitus (2) Immunosuppression/steroid therapy (2) End-stage renal disease (2) Reinterventions (2) Peripheral arterial occlusive disease (1) Nicotine abuse (1) Obesity (BMI \> 30) (1) Age \> 80 years (1) Duration of surgery \> 4 h (1) Blood loss \> 1.5 L (1) Local radiotherapy/chemotherapy (1) Exclusion Criteria: * Pregnancy or breastfeeding * Femoral access for an indication other than PAOD * Preoperative local infection or infectious skin disease * Life expectancy \< 3 months * Active infection of the ipsilateral extremity requiring systemic antibiotic therapy at the time of surgery * Systemic antibiotic therapy at the time of surgery * Use of coated incisional drapes (e.g., iodine-impregnated) * Intraoperative use of anti-infective topical agents (e.g., Gentacoll, doxycycline, etc.) * Use of fibrin sealants/thrombogenic adhesive substances above the fascia Planned postoperative prophylactic negative pressure wound therapy (NPWT)

Primary outcome measure(s)

Time to revision surgery due to inguinal wound healing complications — within 3 months postoperatively

Trial sites (1)

Facility	City	Region	Status
Department of Vascular and Endovascular Surgery	Cologne	North Rhine-Westphalia

Other trials for the same condition

Subcutaneous Suture Versus no Subcutaneous Suture for Abdominal Wound Closure Recruiting

Prevention of Mental Disorders Through Self-efficacy Interventions Recruiting

Troubled-Desire & Therapeutic Chat for Reduction of CSAM Use (TD-CHAT) Recruiting

Evaluation of 7-day vs 1-day Packaging of Small Quantity Lipid-based Nutrition Supplementation (SQ-LNS) Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07571408 on ClinicalTrials.gov ↗ ← All trials in Germany